IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Recent Advances in Quinolines as Anticancer Agents: Mechanisms, SAR, and Therapeutic Potential

[1]L. Architha, [2]Dr. M. Vijaya Bhargavi
[1]Student, [2]Associate professor
[1]Department of Pharmaceutical Chemistry
[1]RBVRR Women's college of pharmacy, Hyderabad, 500027, India

Abstract: Quinolines, a prominent class of nitrogen-containing heterocycles, have emerged as vital scaffolds in medicinal chemistry due to their broad spectrum of biological activities, especially in oncology. Numerous quinoline derivatives exhibit potent anticancer effects by modulating diverse molecular targets such as DNA topoisomerases, receptor tyrosine kinases, autophagy regulators, and apoptotic pathways. This review consolidates current knowledge on quinoline-based anticancer agents, detailing their structural modifications, mechanisms of action, and recent progress in preclinical and clinical studies. The challenges of drug resistance, poor solubility, and systemic toxicity are also highlighted, along with future directions aimed at optimizing quinoline scaffolds for improved efficacy and safety.

IndexTerms **- Quinolines, anticancer agents, topoisomerase inhibitors, kinase inhibitors, autophagy, SAR.**

I. INTRODUCTION

Cancer is a multifactorial disease characterized by uncontrolled cellular proliferation, evasion of apoptosis, sustained angiogenesis, and metastasis. Despite substantial advancements in targeted therapies and immuno-oncology, the need for new chemotypes with multitarget capabilities remains critical due to issues of resistance and non-selectivity. Heterocyclic compounds represent a cornerstone of drug discovery, and among them, quinolines—comprising a benzene ring fused to a pyridine—hold a special place due to their structural adaptability and diverse pharmacodynamics. While initially explored as antimalarials (e.g., chloroquine, quinine), quinolines have shown remarkable promise in oncology. Their planar aromatic structure allows intercalation with DNA, while side-chain modifications enable selective binding to enzymes and receptors implicated in cancer progression.

II. STRUCTURE-ACTIVITY RELATIONSHIP (SAR) INSIGHTS

Structural optimization of quinoline derivatives has yielded significant improvements in anticancer potency. SAR studies highlight that substitution at C-4 and C-7 with electron-withdrawing groups enhances lipophilicity and facilitates DNA intercalation. Amino side chains at C-4 (as in chloroquine) increase lysosomal trapping, useful for disrupting autophagy. Fusion of additional rings, as seen in camptothecin, significantly increases binding affinity to DNA-topoisomerase complexes. Alkoxy or amide groups at C-2 or C-3 improve hydrogen bonding with kinase ATP pockets. Hybrid molecules display synergistic cytotoxicity.

Key insights from SAR studies:

- **C2 & C3:** Amino, carboxy, alkyl substitutions enhance topoisomerase inhibition and DNA binding.
- **C4:** Hydroxyl, lactone groups (as in camptothecin) are crucial for stabilizing DNA cleavage complexes.
- **C6 & C7:** Halogens, methoxy, nitro groups modulate kinase inhibition and improve membrane permeability.
- **C8:** Methoxy or fluorine alters metabolic stability and extends half-life.

For example, 4-hydroxyquinoline derivatives show strong topoisomerase inhibition, while 6,7-dimethoxy substitutions correlate with enhanced activity against VEGFR. Such insights drive rational design.

III. Mechanisms of Anticancer Activity

Quinoline derivatives disrupt cancer progression through several interconnected mechanisms:

1. **DNA Intercalation & Topoisomerase Poisoning:**
   Planar quinoline structures insert between DNA base pairs, stabilizing cleavage complexes formed by topoisomerase I/II, resulting in replication fork collapse and apoptosis.
2. **Cell Cycle Arrest:**
   Many quinolines induce arrest at G2/M or S-phase by downregulating cyclin-dependent kinases.
3. **Apoptosis via Intrinsic Pathway:**
   Elevated ROS levels trigger mitochondrial membrane permeabilization, cytochrome c release, and caspase-9/-3 activation.
4. **Inhibition of RTKs:**
   Substituted quinolines inhibit EGFR and VEGFR, curbing angiogenesis and metastasis.
5. **Anti-metastatic Effects:**
   Lower expression of MMP-2 and MMP-9 reduces extracellular matrix degradation.

3.1 Schematic Diagram of Mechanisms



Figure: Flowchart summarizing key mechanisms of quinoline derivatives in cancer treatment.

IV. Recent Advances and Examples

Examples include:

- **Camptothecin & analogs (Topotecan, Irinotecan):** Topoisomerase I inhibitors for colon and ovarian cancers.
- **Fused quinoline systems (quinoline-pyrazoles):** Nanomolar IC_{50}s against breast and prostate cancer lines.
- **8-Hydroxyquinoline metal chelates:** Inhibit zinc-dependent MMPs, preventing metastasis.
- **Erlotinib (quinazoline analog):** Inhibits EGFR in NSCLC, structurally related.

Key data:
Camptothecin ~0.02 µM (colon), 6,7-dimethoxyquinoline ~0.5 µM (breast), Ru(II)-8HQ ~1 µM (HeLa).

Challenges and Future Directions

Challenges include multidrug resistance due to efflux pumps, off-target toxicity affecting healthy tissues, and pharmacokinetic issues like solubility and rapid metabolism.

Future strategies involve:

- Nano-delivery systems (liposomes, dendrimers)

- Hybrid molecules combining quinolines with HDAC or PARP inhibitors
- AI-driven approaches to predict optimal modifications

CONCLUSION

Quinolines provide a versatile scaffold for anticancer drug development, capable of targeting multiple pathways. Future integration of structural insights with novel delivery platforms promises next-generation quinoline therapeutics with superior efficacy and safety profiles.

REFERENCES

[1] Pommier Y. Chem Rev. 2009;109(7):2894-2902.
[2] Amaravadi RK, et al. Genes Dev. 2016;30(17):1913-1930.
[3] Zhao Y, et al. MedChemComm. 2020;11(4):567-580.
[4] Kashyap D, et al. Eur J Med Chem. 2022;239:114477.
[5] Maheshwari KK, et al. Eur J Pharm Sci. 2021;157:105610.
[6] LoRusso PM, et al. Semin Oncol. 1996;23(1 Suppl 3):56-64.
[7] Zhang J, et al. Nanomedicine. 2021;16(9):711-728.